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Background: This phase II neoadjuvant trial evaluated bevacizumab–docetaxel and carboplatin in triple-negative
breast cancer.
Patients and methods: Women with hormone receptor- and human epidermal growth factor receptor 2 (HER2)-
negative, stage II/III breast cancer received six cycles of 75 mg/m2 docetaxel, carboplatin (AUC = 5) and 15 mg/kg
bevacizumab every 21 days. The primary end point was pathological complete response (pCR) in breasts and axillary
lymph nodes (ALN).
Results: Forty-ﬁve patients were recruited from the Korean Cancer Study Group. The median age was 45 (range
30–72) years. ALNs were positive in 80% of patients (n = 36) at diagnosis. Overall, 98% of patients (n = 44) completed
therapy and underwent surgery. The pCR rate was 42% (n = 19); clinical response rate 96% (n = 43); complete 13%
(n = 6); partial 82% (n = 37); stable disease 2% (n = 1). Breast-conserving surgery was undertaken in 78% of patients
(n = 35). Most frequent grade 3/4 adverse events were neutropenia (84%, n = 38) and febrile neutropenia (9%, n = 4).
One patient experienced delayed wound healing after surgery.
Conclusions: Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and
negligible wound healing problems after surgery.
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triple-negative breast cancer
introduction
Triple-negative breast cancer (TNBC) is characterised as the
lack of expression of oestrogen receptor (ER) and progesterone
receptor (PgR), and the lack of human epidermal growth factor
receptor 2 (HER2) over-expression and/or ampliﬁcation [1, 2],
and accounts for 15%–20% of all breast cancers [3]. The
prognosis for patients with TNBC is poor owing to the
aggressive nature of the disease, including short disease-free
intervals and survival duration after recurrence, high-grade
histology and frequent visceral metastases [4]. Owing to the
lack of an appropriate target, patients with TNBC are not
indicated for treatment with endocrine therapy or with the
anti-HER2 monoclonal antibody trastuzumab. Thus, systemic
treatment options are currently limited to cytotoxic
chemotherapy.
Patients with TNBC who achieve pathological complete
response (pCR) with neoadjuvant therapy have comparable
survival outcomes to patients with non-TNBC. However,
patients with TNBC with residual disease after neoadjuvant
chemotherapy have higher recurrence risk and signiﬁcantly
decreased survival compared with patients with non-TNBC
[4]. Currently, data from clinical studies support the use of
neoadjuvant anthracyclines and taxanes as standard therapy
regardless of breast cancer subtype [3, 5–8]. Recent studies
have suggested overlap between cancers occurring in women†HRK and KHJ were joint lead authors on this manuscript.
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with breast cancer type 1 (BRCA1) mutations, basal-like breast
cancer and TNBC, but the nature of such links remains
unclear [1]. Because of its direct DNA damaging nature, TNBC
appears to be particularly sensitive to platinum analogues [9–
12], especially BRCA1 mutation-associated TNBC [2, 13].
Inhibiting angiogenesis may be another strategy for the
treatment of TNBC, as genes involved in angiogenesis are
frequently activated in basal-like tumours [14]. Bevacizumab, a
monoclonal antibody against vascular endothelial growth
factor (VEGF) A, has demonstrated clinical efﬁcacy in
combination with chemotherapy in patients with HER2-
negative metastatic breast cancer [15], including in subgroups
of patients with metastatic TNBC [16, 17], as well as in the
neoadjuvant setting [18–20]. Indeed, early adoption of
bevacizumab as a neoadjuvant or adjuvant therapy could
maximise its beneﬁt, because trapping of VEGFA, a key
angiogenic factor, would be most effective in the early
carcinogenesis niche where only a few angiogenic factors
exist [21].
In a phase II trial of docetaxel and carboplatin-based
neoadjuvant chemotherapy for stage II/III breast cancer, a
differential response was observed, with highest pCR rates
achieved in patients with TNBC [10]. Based on these results,
and given the sensitivity of TNBC to platinum analogues [9–
12], we designed a single-arm phase II trial of docetaxel,
carboplatin and bevacizumab as neoadjuvant treatment in
patients with stage II/III TNBC. Given the potential for cardiac
toxicity with anthracyclines, we chose a non-anthracycline
chemotherapy regimen for the study.
methods
patients
Women aged ≥20 years (the legal adult age in Korea) with histologically
conﬁrmed stage II/III TNBC were eligible. Patients were required to have
tumours measurable by breast magnetic resonance imaging (MRI),
mammography and physical examination. Axillary lymph node (ALN)
status was deﬁned as positive based on imaging studies including MRI, or
clinical examination followed by conﬁrmed positive aspiration cytology
ﬁndings. Triple negativity was deﬁned as <1% nuclear staining for ER and
PgR by immunohistochemistry (IHC), HER2-negativity of 0 or 1+ by IHC
or HER2 non-ampliﬁcation by ﬂuorescent in situ hybridisation analysis.
Patients were required to have an Eastern Cooperative Oncology Group
performance status of 0–1 and normal organ function. Further relevant
eligibility criteria were normal cardiac function showing left ventricular
ejection fraction (LVEF) ≥55% by echocardiography or multi-gated
acquisition scan, no previous thromboembolic event, no known
haemorrhagic diathesis or coagulopathy, and no major surgery within the
past 28 days or anticipation of a major surgery during the study treatment
period. Patients with active uncontrolled infection were excluded.
The trial was carried out in accordance with the principles of Good
Clinical Practice and the Declaration of Helsinki. The protocol was
approved by the Protocol Review Committee of the Korean Cancer Study
Group and by the Institutional Review Board in each participating institute.
All patients provided written informed consent before any study-related
procedure (ClinicalTrials.gov identiﬁer: NCT01208480; protocol number:
KCSG BR-0905).
study design
This was a single-arm, phase II, multicentre study of bevacizumab,
docetaxel and carboplatin as neoadjuvant treatment in patients with
TNBC. Patients received six cycles of 15 mg/kg bevacizumab, 75 mg/m2
docetaxel and carboplatin (AUC = 5) on the ﬁrst day of every 21 days.
Bevacizumab was omitted in the last cycle to avoid wound complications.
Patients were to undergo breast surgery 4–6 weeks after administration of
the last cycle of chemotherapy to prevent wound complications. Treatment
continued for six cycles unless there was disease progression, unacceptable
toxicity or withdrawal of consent. If there was tumour progression during
treatment, study treatment was discontinued and further local or systemic
treatment was permitted at the investigator’s discretion. During the ﬁrst
cycle, complete blood counts and biochemistry tests were carried out on
days 10–14. Thereafter, if there were no adverse events, they were carried
out before each cycle and as clinically indicated.
Chemotherapy dose adjustments were made if, on the planned day of
therapy, absolute neutrophil count was <1.5 × 109/l and/or platelet count
was <100 × 109/l, chemotherapy was delayed until these criteria were met.
A maximum postponement of 3 weeks was allowed. Chemotherapy dose
reductions were carried out in patients who had grade 4 neutropenia or
thrombocytopenia lasting >7 days and in patients with febrile neutropenia
(>38.5°C) associated or not associated with documented infection. Study
treatment was interrupted and the dose reduced for patients who
experienced a second occurrence of grade 2 non-haematological toxicity
(except alopecia, nausea/vomiting or peripheral neuropathy) or any grade 3
toxicity. All non-haematological toxic effects must have subsided to grade
≤1 before re-starting treatment. Subsequent treatment such as adjuvant
chemotherapy and radiotherapy were allowed at the discretion of the
investigator. Granulocyte colony-stimulating factor (G-CSF) support was
used according to standard guidelines and at the investigator’s discretion.
study end points
The primary end point of the study was pCR rate, deﬁned as the absence of
invasive disease in the primary breast and ALN (i.e. pathology stage T0N0
or TisN0). Secondary end points were: clinical response rates of breast
tumours and ALNs, as assessed by physical examination and imaging
studies; toxicity; the rate of breast pCR, regardless of ALN; and the rate of
breast-conserving surgery (BCS).
assessment of end points
Radiological imaging tests, medical history and physical examination were
carried out within 14 days before treatment. Tumour measurements were
scheduled at baseline, and after cycles 3 and 6 for lesions assessed
radiographically. The target lesion and regional lymph nodes were
examined by palpation at every cycle. Pathological responses of the breast
tumour and inﬁltration of regional lymph nodes were assessed and staged
according to the tumour-node-metastatic system. Clinical complete
response was assessed by breast MRI and Response Evaluation Criteria in
Solid Tumors (RECIST) version 1.1 [22]. Toxic effects were assessed at the
end of each cycle according to the National Cancer Institute’s Common
Terminology Criteria for Adverse Events, version 3.0. Patients were
considered to have had BCS if the ﬁnal surgical procedure was
tumourectomy, segmentectomy or quadrantectomy.
statistical design
All patients who received at least one cycle of bevacizumab, docetaxel and
carboplatin were included in the intent-to-treat (ITT) population. The
Fleming single-stage design assumed the expected pCR to be at least 37%
and the minimum acceptable pCR as 20% [4]. Thus, 45 patients were
required to provide a power of 80% and a 5% chance of type I error.
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From October 2010 to December 2011, 45 women with stage
II/III TNBC were enrolled at seven centres in Korea; these 45
patients received at least one dose of study treatment and were
included in all efﬁcacy and safety analyses (ITT population).
Forty-four patients completed six cycles of therapy followed by
surgery (per protocol population). One patient declined
further treatment after cycle 3 and was withdrawn from the
study; this patient showed complete response after the third
cycle of study treatment, as assessed by breast MRI.
Baseline characteristics of the 45 eligible patients are shown
in Table 1. The median patient age was 45 (range 30–72) years
and the median tumour size was 3.9 cm, as assessed by breast
MRI. Overall, 4%, 69% and 27% of patients had stage cT1, cT2
and cT3 disease, respectively. ALNs were clinically positive in
80% of patients at diagnosis (16 patients were diagnosed based
on aspiration cytology). Based on preoperative breast MRI,
16% of patients had stage IIA tumours, 64% had stage IIB
tumours and 20% had stage IIIA tumours. All patients had
histological type invasive ductal carcinoma. Additionally, 2.2%,
26.6% and 62.2% of patients had tumours of histological grade
1, 2 and 3, respectively.
efﬁcacy outcomes
The primary end point, the rate of pCR in both breast and
ALN, in the ITT population was 42% [95% conﬁdence interval
(CI) 27.8–56.6] (n = 19) (Table 2). Thus, the null hypothesis
according to the Fleming design was rejected. The rate of pCR
in the breast only was 44% (95% CI 29.9–58.9) (n = 20). Based
on RECIST and breast MRI, 96% of patients (n = 43)
experienced a clinical response [six complete responders (13%)
and 37 partial responders (82%)], one patient showed stable
disease, and one patient was not evaluated due to withdrawn
consent.
The median sum of target lesions in the breast and ALN was
4.35 cm at baseline, 1.83 cm after the third cycle and 1.30 cm
after the sixth cycle. Most patients showed remarkable tumour
shrinkage during the ﬁrst three cycles; however, in an
exploratory ﬁnding, a few patients responded to the last three
cycles of treatment despite having stable disease during the
ﬁrst three cycles (supplementary Figure S1, available at Annals
of Oncology online). Following surgery, besides a pCR rate of
42%, 49% of patients (n = 22) exhibited a T stage of I or II.
BCS was carried out in 78% (95% CI 65.5–89.9) of patients
(n = 35) (Table 2).
safety
All grade treatment-emergent adverse events are listed in
Table 3. Treatment was generally well tolerated. Twelve
patients (27%) experienced grade 1 bleeding events (epistaxis,
n = 8; oral mucosal bleeding, n = 3; menorrhagia, n = 1) and
one patient (2%) experienced grade 2 bleeding (anal bleeding).
Bevacizumab-related arterial hypertension developed in eight
patients (18%) at the grade 1 level. Only one patient (2%)
experienced delayed wound healing after breast surgery; the
wound was completely recovered 3 weeks after the operation
and did not affect the radiation therapy schedule. The most
frequently reported grade 3/4 adverse events were neutropenia
(84%, n = 38), febrile neutropenia (9%, n = 4) and vomiting
(7%, n = 3). No cases of congestive heart failure (CHF) were
reported.
Table 2. Summary of treatment outcomes
n (%) [95% CI] ITT population
(N = 45)
pCR (absence of invasive disease in breast and
ALN)
19 (42.2) [27.8–56.6]




Complete response 6 (13.3) [3.4–23.2]
Partial response 37 (82.2) [71.0–93.4]
Stable disease 1 (2.2) [−2.1–6.5]
Progressive disease 0
Not evaluable 1 (2.2) [−2.1–6.5]
BCS
Yes 35 (77.7) [ 65.5–89.9]
No 9 (20.0) [8.3–31.7]
No surgerya 1 (2.2) [−2.1–6.5]
aOne patient refused surgery and was subsequently withdrawn.
CI, conﬁdence interval; ITT, intent-to-treat; pCR, pathological complete
response; ALN, axillary lymph nodes; BCS, breast-conserving surgery.
Table 1. Baseline demographic and clinical characteristics
ITT population (N = 45)
Female, n (%) 45 (100)
Median age, years (range) 45 (30–72)
Invasive ductal carcinoma, n (%) 45 (100)
ECOG performance status, n (%)
0 44 (98)
1 1 (2)
Median largest tumour diameter, cm (range) 3.9 (0.6–11.3)




Pre-chemotherapy N stage, n (%)
Node positive 36 (80.0)
Node negative 9 (20.0)








Not available 4 (8.9)
ITT, intent-to-treat; ECOG, Eastern Cooperative Oncology Group; AJCC,
American Joint Committee on Cancer.
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In total, 98% of patients (n = 44) received all six cycles of
treatment, including ﬁve cycles of bevacizumab, and
underwent breast surgery. G-CSF was supported in 72/267
(27%) cycles. Chemotherapy was delayed in seven patients
(16%) due to febrile neutropenia (n = 4), grade 3 stomatitis
(n = 1), schedule of response evaluation (n = 1) and grade 3
vomiting (n = 1). The chemotherapy dose was reduced in eight
patients (18%) due to febrile neutropenia (n = 4), grade 3
vomiting (n = 3) and grade 3 stomatitis (n = 1). A relative dose
intensity >85% was achieved in 78% of patients (n = 35). The
median bevacizumab-free interval, deﬁned as the time between
the starting date of the last cycle and the date of surgery, was
4.3 (range 3.7–6.0) weeks.
Forty-two patients received radiation therapy after breast
surgery. Six patients underwent adjuvant chemotherapy, three
patients received cyclophosphamide, methotrexate and
ﬂuorouracil, and a further three patients received doxorubicin–
cyclophosphamide.
discussion
Results of this phase II study showed that bevacizumab
combined with docetaxel and carboplatin as neoadjuvant
treatment resulted in an encouraging pCR rate (42%) in
patients with TNBC. Adverse events were manageable; the only
postoperative complication was a single case of wound healing
delay. Our data compare favourably with published data in
TNBC, including a pCR rate of 35% reported in the I-SPY trial
of sequential neoadjuvant anthracyclines and taxanes [23]. To
the best of our knowledge, no other article has reported data
on the combination of neoadjuvant bevacizumab and
chemotherapy exclusively in patients with TNBC. One
neoadjuvant study was presented in abstract form, which is the
combination of cisplatin with bevacizumab in patients with
TNBC and reported a pCR of 15%; overall, 5% of patients did
not complete therapy because of toxic effects [24]. The
difference in terms of pCR rate between that study and our
study (42% versus 15%) could be attributed to the baseline
chemotherapy regimen, as we used docetaxel–carboplatin
rather than single-agent cisplatin.
We acknowledge the limitations of our study, given the lack
of a control arm and the relatively small sample size, and
suggest that results from a randomised study of patients with
TNBC would be more informative. Indeed, data from
randomised trials investigating the role of platinum and taxane
in this setting are awaited. One such study, CALGB 40603, will
examine the addition of carboplatin with or without
bevacizumab to neoadjuvant paclitaxel followed by
doxorubicin–cyclophosphamide (AC) in HER2-negative
resectable breast cancer.
Recently, two randomised, phase III studies revealed
signiﬁcant improvements in pCR rates with the addition of
bevacizumab to neoadjuvant therapy in operable or locally
advanced breast cancer (Table 4) [18, 19]. In GeparQuinto,
patients received epirubicin–cyclophosphamide followed by
docetaxel with or without bevacizumab [18]. In NSABP B-40,
patients received docetaxel alone or in combination with
capecitabine or gemcitabine, with or without bevacizumab for
the ﬁrst six cycles, all followed by AC [19]. These trials were
conducted in patients with HER2-negative breast cancer,
including hormone receptor-positive and -negative tumours. In
the NSABP B-40 trial, the combination of bevacizumab with
chemotherapy signiﬁcantly increased the pCR rate in the breast
(pT0N0/+/pTisN0/+) from 28% to 35% (P = 0.02), which was
the primary end point of the study [19]. Subgroup analyses
showed that pCR rates (breast only) in patients with TNBC
receiving or not receiving bevacizumab were 52% and 47%,
respectively, representing a numerical increase without
statistical signiﬁcance (P = 0.34) [19]. The GeparQuinto trial
demonstrated a signiﬁcant improvement in pCR rate (breast
and ALN: pT0N0) with the addition of bevacizumab to
neoadjuvant chemotherapy in the overall population (15%
versus 18%, respectively, odds ratio 1.29, 95% CI 1.02–1.65;
P = 0.04) as well as in patients with TNBC (39% versus 28%,
respectively; P = 0.003) [18]. Although patient baseline
characteristics in our study, including tumour size, nodal status
and tumour grade, differed from NSABP B-40 and
GeparQuinto, the pCR rate of 42% (breast and ALN) was
comparable with that achieved in patients with TNBC in those
studies. Furthermore, the BCS rate of 78% was higher than that
in GeparQuinto (62%) and NSABP B-40 (47%), as was the
clinical response rate [18, 19]. These results could be
attributable to the relatively early-stage tumours included in
Table 3. All grade treatment-emergent adverse events
n (%)a Safety population (N = 45)
Grade 1 Grade 2 Grade 3 Grade 4
Haematological toxicity
Neutropenia 0 1 (2.2) 6 (13.3) 32 (71.1)
Febrile neutropenia NA NA 4 (8.9) –
Anaemia 2 (4.4) 3 (6.7) 1 (2.2) –
Thrombocytopenia 2 (4.4) – 1 (2.2) –
Non-haematological toxicity
Stomatitis/mucositis 24 (53.3) 9 (20.0) 1 (2.2) –
Fatigue 9 (20.0) 5 (11.1) – –
Infection 1 (2.2) 1 (2.2) – –
Hypertension 8 (17.6) – – –
Bleeding 12 (26.7) 1 (2.2) – –
Conjunctivitis – 3 (6.7) – –
Diarrhoea 14 (31.1) 8 (17.8) – –
Constipation 16 (35.6) 5 (11.1) – –
Skin discolouration 13 (28.9) 7 (15.6) – –
Anorexia 10 (22.2) 5 (11.1) – –
Nausea 27 (60.0) 6 (13.3) 2 (4.4) –
Vomiting 7 (15.6) 3 (6.7) 3 (6.7) –
Increased ALT – – 1 (2.2) –
Peripheral neuropathy 20 (44.4) 3 (6.7) – –
Alopecia 9 (20.0) 26 (57.8) – –
Arthralgia 1 (2.2) 1 (2.2) – –
Myalgia 16 (35.6) 7 (15.6) – –
Allergic reaction 2 (4.4) 2 (4.4) – –
Oedema 10 (22.2) – – –
aPatients may have experienced more than one adverse event.
ALT, alanine aminotransferase.
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our trial, but caution should be exercised when making cross-
trial comparisons.
Bevacizumab-related postoperative wound complications are
of concern in the neoadjuvant setting. Recent data suggest that
neoadjuvant bevacizumab may be associated with an increased
risk of major postoperative complications, including wound
dehiscence and seroma, especially among women undergoing
breast reconstruction with tissue expanders [25]. In contrast,
two large randomised, phase III studies and our study recorded
few postoperative wound complications with neoadjuvant
bevacizumab [10, 19, 26]. To avoid postoperative wound
complications our study protocol speciﬁed that bevacizumab
should be omitted in the last cycle, with surgery carried out at
least 28 days after administration of the last cycle. A similar
design was employed in the phase III studies.
Most adverse events reported during the study were
manageable. Grade 3/4 neutropenia was the most frequently
reported adverse event. There were no grade ≥3 bevacizumab-
related events, such as hypertension or bleeding. One patient
refused further therapy after the third cycle and was withdrawn
from the study; this patient had a complete response as
assessed by breast MRI.
A recent meta-analysis examining bevacizumab-related
cardiac toxicity in patients with metastatic breast cancer
demonstrated a 1.6% incidence of high-degree CHF in
bevacizumab-treated patients compared with 0.4% for placebo
[26]. In our trial, no case of CHF was reported using a non-
anthracycline-based regimen in combination with bevacizumab.
However, it must be remembered that, while most of the
patients treated with bevacizumab in the metastatic setting had
been exposed to anthracyclines, none of the patients on the
current trial had ever received an anthracycline. The median
LVEF of 15 patients, which was not mandatory, was unchanged
after treatment compared with baseline (data not shown).
Although TNBC seems to be a heterogeneous disease
clustered as several subtypes, as shown in recent gene
expression proﬁles, it would be essential to focus on TNBC in
future phase III clinical trials; these patients have a distinct
disease that differs from both luminal disease and HER2-
positive breast cancer [27]. Data from the ongoing, open-label,
randomised, phase III BEATRICE study will deﬁne the role of
bevacizumab added to standard anthracycline-/taxane-
containing adjuvant chemotherapy, speciﬁcally in patients with
TNBC, with invasive disease-free survival as the primary end
point (ClinicalTrials.gov identiﬁer: NCT00528567). Further
neoadjuvant clinical trials that enrol only patients with TNBC
are warranted to deﬁne the role of bevacizumab in this patient
group. For this purpose, a docetaxel and carboplatin backbone
would be a reasonable choice because of its clinical evidence of
sensitivity to TNBC and non-overlapping toxicity with
bevacizumab in terms of cardiac function.
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